全文获取类型
收费全文 | 2758篇 |
免费 | 218篇 |
国内免费 | 72篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 53篇 |
妇产科学 | 39篇 |
基础医学 | 354篇 |
口腔科学 | 43篇 |
临床医学 | 281篇 |
内科学 | 650篇 |
皮肤病学 | 33篇 |
神经病学 | 230篇 |
特种医学 | 145篇 |
外科学 | 547篇 |
综合类 | 77篇 |
预防医学 | 111篇 |
眼科学 | 55篇 |
药学 | 156篇 |
中国医学 | 9篇 |
肿瘤学 | 253篇 |
出版年
2023年 | 15篇 |
2022年 | 8篇 |
2021年 | 39篇 |
2020年 | 30篇 |
2019年 | 40篇 |
2018年 | 62篇 |
2017年 | 38篇 |
2016年 | 59篇 |
2015年 | 81篇 |
2014年 | 83篇 |
2013年 | 133篇 |
2012年 | 197篇 |
2011年 | 153篇 |
2010年 | 92篇 |
2009年 | 112篇 |
2008年 | 162篇 |
2007年 | 205篇 |
2006年 | 169篇 |
2005年 | 177篇 |
2004年 | 155篇 |
2003年 | 117篇 |
2002年 | 105篇 |
2001年 | 98篇 |
2000年 | 76篇 |
1999年 | 66篇 |
1998年 | 32篇 |
1997年 | 45篇 |
1996年 | 33篇 |
1995年 | 27篇 |
1994年 | 19篇 |
1993年 | 21篇 |
1992年 | 50篇 |
1991年 | 25篇 |
1990年 | 32篇 |
1989年 | 38篇 |
1988年 | 39篇 |
1987年 | 35篇 |
1986年 | 29篇 |
1985年 | 25篇 |
1984年 | 13篇 |
1983年 | 14篇 |
1982年 | 12篇 |
1981年 | 8篇 |
1980年 | 8篇 |
1979年 | 7篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1976年 | 10篇 |
1974年 | 8篇 |
1968年 | 6篇 |
排序方式: 共有3048条查询结果,搜索用时 31 毫秒
1.
Darren Ming‐Chun Poon 《Asia-Pacific Journal of Clinical Oncology》2020,16(Z3):18-23
For advanced and metastatic urothelial carcinomas (UCs), platinum (preferably cisplatin)‐based chemotherapy has been the standard treatment for many years. However, many patients are ineligible for cisplatin‐based chemotherapy because of poor performance status and/or other age‐related conditions. At the other end of the spectrum, patients with localized non‐muscle–invasive bladder cancer who are unresponsive to intravesical Bacillus Calmette‐Guérin (BCG) treatment often face radical cystectomy as the only option. In recent years, the application of immunotherapy in the form of immune‐checkpoint inhibitors has provided viable alternatives in the second‐line postplatinum and first‐line cisplatin‐ineligible settings. Recent and ongoing clinical trials are also assessing the safety and efficacy of immunotherapy for neoadjuvant and adjuvant uses before/after cystectomy, for BCG‐unresponsive cases, and for combination treatments that include the newer indoleamine 2,3‐dioxygenase‐1 inhibitors and/or BCG. This review summarizes recent developments in immunotherapy for UCs. 相似文献
2.
3.
4.
5.
The duration of the masseteric EMG silent period as induced by tapping on the chin was measured at different levels of sustained bite force. Under both open bite and normal occlusion, the duration of the silent period was inversely related to the magnitude of the bite force. For bite force of the same magnitude, the value of the silent period remained relatively constant for the same subject in different trials (SEM ? 1 per cent), whereas the absolute values of the silent periods ranged far and wide for different individuals even under similar experimental conditions. 相似文献
6.
7.
8.
Carbamazepine (CBMZP) has been implicated as an inhibitor of the activities of 5-aminolaevulinic acid dehydratase (ALA-D) and uroporphyrinogen I synthetase (URO-S). In an epileptic boy undergoing long-term treatment with valproic acid (VPA), 1.3 g/d, CBMZP, 0.9 g/d and folic acid, 7.5 mg/d, decreased activities of ALA-D and URO-S coincided with increased levels of erythrocyte protoporphyrin (EP) in the absence of Pb poisoning, iron depletion and erythropoietic protoporphyria. A progressive fall in plasma pyridoxal 5'-phosphate (B6-P) to 7.7 nmol/L (lower reference limit, 14.6 nmol/L) prompted implementation of pyridoxine HCl (B6-HCl), 87.5 mg/d followed by administration of both B6-HCl and preformed B6-P (50 mg/d each). This permitted the eventual withdrawal of VPA and a net reduction of CBMZP to 450 mg/d. During these manipulations, ALA-D and URO-S activities, EP and urinary porphyrins and their precursors were measured serially. An assay system utilizing red cell ALA-D for generation of porphobilinogen (PBG) from added ALA at pH 7.4 was used for determination of ALA-D and URO-S activities in separate aliquots of the same assay mixture both in the absence and presence of Zn and dithiothreitol (DTT). One unit (U) for ALA-D = 1 nmol PBG/L RBC/s; for URO-S = 1 nmol porphyrin/L/s; minimum normal level for ALA-D = 135 U; for URO-S = 6 U. B6-HCl alone entailed increases in ALA-D and URO-S prior to any reduction of CBMZP. After administration of both B6-HCl and B6-P and withdrawal of VPA, the overall increase in ALA-D was from 54.59 to 197.2 U (-Zn; -DTT) and from 50.76 to 217.3 U (+Zn; +DTT). The overall increase in URO-S was from 2.67 to 8.90 U (-Zn; -DTT) and from 3.02 to 8.66 U (+Zn; +DTT). During stepwise reduction of VPA, EP remained elevated to values as high as 2.48 mumol/L (upper reference limit, 1.33 mumol/L). Only after permanent withdrawal of VPA did concentrations of EP fall to normal levels. Values for porphyrins and their precursors in urine were normal throughout. Since both VPA and B6-P are strongly protein-bound, it is suggested that VPA displaced B6-P from protective protein binding sites and that the resulting deficit in B6-P (rather than CBMZP) reduced ALA-D and URO-S activities via primary reduction of ALA-synthetase activity. Increases in EP emerge as a hitherto unappreciated effect of VPA warranting further investigation. 相似文献
9.
Andrew X. Zhu MD Darrell R. Borger MD Yuhree Kim MD David Cosgrove MD Aslam Ejaz MD Sorin Alexandrescu MD Ryan Thomas Groeschl MD Vikram Deshpande MD James M. Lindberg MD Cristina Ferrone MD Christine Sempoux MD Thomas Yau MD Ronnie Poon MD Irinel Popescu MD Todd W. Bauer MD T. Clark Gamblin MD Jean Francois Gigot MD Robert A. Anders MD Timothy M. Pawlik MD MPH PhD 《Annals of surgical oncology》2014,21(12):3827-3834
Background
The molecular alterations that drive tumorigenesis in intrahepatic cholangiocarcinoma (ICC) remain poorly defined. We sought to determine the incidence and prognostic significance of mutations associated with ICC among patients undergoing surgical resection.Methods
Multiplexed mutational profiling was performed using nucleic acids that were extracted from 200 resected ICC tumor specimens from 7 centers. The frequency of mutations was ascertained and the effect on outcome was determined.Results
The majority of patients (61.5 %) had no genetic mutation identified. Among the 77 patients (38.5 %) with a genetic mutation, only a small number of gene mutations were identified with a frequency of >5 %: IDH1 (15.5 %) and KRAS (8.6 %). Other genetic mutations were identified in very low frequency: BRAF (4.9 %), IDH2 (4.5 %), PIK3CA (4.3 %), NRAS (3.1 %), TP53 (2.5 %), MAP2K1 (1.9 %), CTNNB1 (0.6 %), and PTEN (0.6 %). Among patients with an IDH1-mutant tumor, approximately 7 % were associated with a concurrent PIK3CA gene mutation or a mutation in MAP2K1 (4 %). No concurrent mutations in IDH1 and KRAS were noted. Compared with ICC tumors that had no identified mutation, IDH1-mutant tumors were more often bilateral (odds ratio 2.75), while KRAS-mutant tumors were more likely to be associated with R1 margin (odds ratio 6.51) (both P < 0.05). Although clinicopathological features such as tumor number and nodal status were associated with survival, no specific mutation was associated with prognosis.Conclusions
Most somatic mutations in resected ICC tissue are found at low frequency, supporting a need for broad-based mutational profiling in these patients. IDH1 and KRAS were the most common mutations noted. Although certain mutations were associated with ICC clinicopathological features, mutational status did not seemingly affect long-term prognosis. 相似文献10.